Skip to main content
Publications
Grange F, Mohr P, Harries M, Ehness R, Benjamin L, Siakpere O, Barth J, Stapelkamp C, Pfersch S, McLeod LD, Kaye JA, Wolowacz S, Kontoudis I. Economic burden of advanced melanoma in France, Germany, and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study). Melanoma Res. 2017 Dec;27(6):607-18. doi: 10.1097/CMR.0000000000000372
Strober B, Zhao Y, Herrera V, Wolin D, McLeod L, Eid D, Bello T. Secukinumab provides greater symptom control in psoriasis-related pain, itching, and scaling compared with previous treatments: evidence from a real-world study in the US. Poster presented at the 26th EADV Congress; September 13, 2017. Geneva, Switzerland.
Harries M, Mohr P, Grange F, Ehness R, Benjamin L, Siakpere O, Barth J, Stapelkamp C, Pfersch S, McLeod L, Wolowacz S, Kaye JA, Kontoudis I. Treatment patterns and outcomes of Stage IIIB/IIIC melanoma in France, Germany and the UK: a retrospective and prospective observational study (MELABIS). Int J Clin Pract. 2017 May 16;71(5):e12946. doi: 10.1111/ijcp.12946
Strober B, Gottlieb AB, Sherif B, Mollon P, Gilloteau I, McLeod L, Fox T, Mordin M, Gnanasakthy A, Papavassilis C, Lebwohl MG. Secukinumab sustains early patient-reported outcome benefits through 1 year: results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. J Am Acad Dermatol. 2017 Apr;76(4):655-61. doi: 10.1016/j.jaad.2016.11.043
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B, McLeod L, Nyirady J, Tyring S. Secukinumab provides better relief from quality-of-life impact than placebo in moderate to severe psoriasis. Poster presented at the 17th Annual Las Vegas Dermatology Seminar & the 13th Annual Psoriasis Forum; November 12, 2016. Las Vegas, NV.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B, McLeod L, Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis. Poster presented at the SDPA 14th Annual Fall Dermatology Conference 2016; November 6, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B, McLeod L, Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis. Poster presented at the 35th Anniversary Fall Clinical Dermatology Conference; October 23, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B, McLeod L, Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis. Poster presented at the Maui Derm NP+ PA Fall 2016; September 29, 2016. Asheville, NC. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Strober B, Jazayeri S, Thaci D, Augustin M, Zhou Y, Gilloteau I, McLeod LD, Sherif B, Herrera V, Nyirady J, Guana A, Lebwohl M. Secukinumab provides faster and more sustained 52-week complete relief from psoriasis-related pain, itching, and scaling than ustekinumab in subjects with moderate-to-severe plaque psoriasis. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Proctor C, McBride D, Balp M-M, McLeod L, Hunter S, Tian H, Khalil S, Hollis K, Maurer M. Comparison of twice-daily and once-daily Urticaria Activity Score: results from the first international burden of illness ASSURE-CSU study in inadequately-controlled chronic spontaneous (idiopathic) urticaria. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Vender R, Leonardi C, Puig L, Ziv M, Zhou Y, Gilloteau I, Sherif B, McLeod LD, Nyirady J, Guana A, Strober B. Secukinumab provides greater cumulative 52-week skin clearance and quality of life benefit in patients with moderate-to-severe plaque psoriasis than ustekinumab: an area under the curve analysis. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Lebwohl M, Blauvelt A, Augustin M, Zhao Y, Gilloteau I, Herrera V, Milutinovic M, You R, Mordin M, McLeod L, Strober B. Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling. Poster presented at the 2016 AAD Summer Meeting; July 2016. Boston, MA.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B, McLeod L, Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis. Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1051
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Tran MH, Karpov A, McLeod LD, Mordin M, Papavassils C, Nyirady J, Lebwohl M. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol. 2016 Apr;55(4):401-7. doi: 10.1111/ijd.13236
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Tran MH, Karpov A, McLeod LD, Mordin M, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab improves patient‐reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo‐controlled clinical trials. Int J Dermatol. 2016 Apr;55(4):401-7. doi: 10.1111/ijd.13236
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the 15th Annual Caribbean Dermatology Symposium; January 26, 2016. Grand Cayman. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the 12th Annual Maui Derm for Dermatologists 2016 Conference; January 25, 2016. Maui, HI. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the Winter Clinical Dermatology Conference; January 15, 2016. Kauai, HI. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the SDPA 13th Annual Fall Dermatology Conference 2015; November 12, 2015. Orlando, FL. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the 16th Annual Las Vegas Dermatology Seminar; November 5, 2015. Las Vegas, NV. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the erasure and fixture trials. Poster presented at the Fall Clinical Dermatology Conference; October 2015. Las Vegas, NV. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Gottlieb A, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Tran MH, McLeod L, Odom D, Elewski B. Secukinumab in psoriasis: relationship between clinical- and patient-reported outcomes using clinical trial data from the erasure and fixture trials. Poster presented at the Fall Clinical Dermatology Conference; October 2015. Las Vegas, NV. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the erasure and fixture trials. Poster presented at the 2nd Annual Maui Derm NP+PA Fall 2015 Meeting; September 2015. Washington, DC. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Gottlieb A, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Tran MH, McLeod L, Odom D, Elewski B. Secukinumab in psoriasis: relationship between clinical- and patient-reported outcomes using clinical trial data from the erasure and fixture trials. Poster presented at the 2nd Annual Maui Derm NP+PA Fall 2015 Meeting; September 2015. Washington, DC. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the erasure and fixture trials. Poster presented at the National Psoriasis Foundation 2015 National Volunteer Conference; July 2015. San Francisco, CA. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Gottlieb A, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Tran MH, McLeod L, Odom D, Elewski B. Secukinumab in psoriasis: relationship between clinical- and patient-reported outcomes using clinical trial data from the ERASURE and FIXTURE trials. Poster presented at the National Psoriasis Foundation 2015 National Volunteer Conference; July 2015. San Francisco, CA. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Lebwohl M, Gottlieb AB, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod LD, Mordin MM, Nelson LM, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the Psoriasis Symptom Diary from the ERASURE and FIXTURE trials. Poster presented at the 73rd Annual Meeting of the American Academy of Dermatology; March 20, 2015. San Francisco, CA.
Gottlieb AB, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Tran MH, McLeod L, Odom D, Elewski B. Secukinumab in psoriasis: relationship between clinical- and patient-reported outcomes using clinical trial data from the ERASURE and FIXTURE trials. Poster presented at the 73rd Annual Meeting of the American Academy of Dermatology; March 2015. San Francisco, CA.
Elewski B, Lebwohl M, Strober B, Szepietowski JC, Blauvelt A, Schlessinger J, Nyirady J, Zhao Y, Tran MH, McLeod L, Odom D, Gottlieb AB. Secukinumab in psoriasis: early improvement in patient-reported symptom diary predicts clinical response. Poster presented at the 73rd Annual Meeting of the American Academy of Dermatology; March 2015. San Francisco, CA.
Kontoudis I, Harries M, Mohr P, Grange F, Ehness R, Benjamin L, Siakpere O, Barth J, Stapelkamp C, Pfersch S, McLeod LD, Kaye JA, Wolowacz SE. Economic burden of melanoma in three European countries: a retrospective observational study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands.